Author(s): Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ,
Abstract Share this page
Abstract BACKGROUND: There are limited studies of stent thrombosis in the modern era of second-generation stents, high-pressure deployment, and current antithrombotic regimens. METHODS AND RESULTS: Six recently completed coronary stent trials and associated nonrandomized registries that enrolled 6186 patients (6219 treated vessels) treated with >/=1 coronary stent followed by antiplatelet therapy with aspirin and ticlopidine were pooled for this analysis. Within 30 days, clinical stent thrombosis developed in 53 patients (0.9\%). The variables most significantly associated with the probability of stent thrombosis were persistent dissection NHLBI grade B or higher after stenting (OR, 3.7; 95\% CI, 1.9 to 7.7), total stent length (OR, 1.3; 95\% CI, 1.2 to 1.5 per 10 mm), and final minimal lumen diameter within the stent (OR, 0.4; 95\% CI, 0.2 to 0.7 per 1 mm). Stent thrombosis was documented by angiography in 45 patients (0.7\%). Clinical consequences of angiographic stent thrombosis included 64.4\% incidence of death or myocardial infarction at the time of stent thrombosis and 8.9\% 6-month mortality. CONCLUSIONS: Stent thrombosis occurred in <1.0\% of patients undergoing stenting of native coronary artery lesions and receiving routine antiplatelet therapy with aspirin plus ticlopidine. Procedure-related variables of persistent dissection, total stent length, and final lumen diameter were significantly associated with the probability of stent thrombosis. Continued efforts to eliminate this complication are warranted given the serious clinical consequences.
This article was published in Circulation
and referenced in Journal of Pharmacogenomics & Pharmacoproteomics